منابع مشابه
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer.
BACKGROUND Please see Appendix 4 for a glossary of terms.The outcome of patients with esophageal cancer is generally poor. Although multimodal therapy is standard, there is conflicting evidence regarding the addition of esophagectomy to chemoradiotherapy. OBJECTIVES To compare the effectiveness and safety of chemoradiotherapy plus surgery with that of chemoradiotherapy alone in people with no...
متن کاملPreoperative chemoradiotherapy for esophageal or junctional cancer.
BACKGROUND The role of neoadjuvant chemoradiotherapy in the treatment of patients with esophageal or esophagogastric-junction cancer is not well established. We compared chemoradiotherapy followed by surgery with surgery alone in this patient population. METHODS We randomly assigned patients with resectable tumors to receive surgery alone or weekly administration of carboplatin (doses titrate...
متن کاملPreoperative concomitant chemoradiotherapy in esophageal cancer
Background. Currently primary treatment options for esophageal cancer are surgery only or concomitant chemoradiotherapy (CRT) and the long-term survival of patients with locally advanced disease is rare. Preoperative concomitant CRT seems to be beneficial, mostly in patients who achieve a complete pathologic response (pCR) after CRT. In this retrospective analysis the efficiency and toxicity of...
متن کاملA Meta-Analysis of Concurrent Chemoradiotherapy for Advanced Esophageal Cancer
BACKGROUND Concurrent chemoradiotherapy is a standard treatment for local advanced esophageal cancer, but the outcomes are controversial. Our goals were to compare the therapeutic effects of concurrent chemoradiotherapy and radiotherapy alone in local advanced esophageal cancer using meta-analysis. METHODS MEDLINE, EMBASE and the Cochrane library were searched for studies comparing chemoradio...
متن کاملClinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer
Platinum-based chemotherapy is considered a standard treatment option for patients with metastatic esophageal carcinoma. However, the overall survival of patients receiving such treatment is <1 year. A common presenting symptom of esophageal cancer is dysphagia, which has a substantial impact on quality of life. We have now retrospectively evaluated the efficacy and safety of palliative chemora...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Korean Journal of Helicobacter and Upper Gastrointestinal Research
سال: 2019
ISSN: 1738-3331,2671-826X
DOI: 10.7704/kjhugr.2019.19.3.161